Eli Lilly has asked to join in opposing a lawsuit brought by compounding pharmacies against the U.S. Food and Drug ...

Eli Lilly and Novo Nordisk are the two biggest names in the pharmaceutical sector, but I see one as the clear-cut winner for ...

Lilly said it plans to publish results of the study next year a peer-reviewed journal and present findings at a medical meeting. U.S. approvals for the medicines was based on separate trials in ...

It is tailored to patients being treated with Lilly's oncology drugs – which ... than 30 DiGAs that have approved for use by the BfArM medical regulator and are covered by the national GKV ...

As Novo Nordisk and Eli Lilly expand sales of their popular diabetes and weight-loss drugs, cheaper copies of their patented ...

The FDA has expanded the approval of Eli Lilly’s obesity medication Zepbound to include treating moderate to severe ...

Glass, senior vice president of global medical affairs at Lilly Cardiometabolic Health, said in a statement on Wednesday. “Zepbound is in a class of its own as the only FDA-approved dual GIP and ...

Lilly will continue to evaluate the SURMOUNT-5 results, which will be published in a peer-reviewed journal and presented at a medical meeting next year. Tirzepatide is commercialized for adults ...

as health authorities in Britain considered doing earlier this year before approving Lilly's drug. An analysis of health records and other data published by the medical journal JAMA Internal ...

The full results will be published in a peer-reviewed journal and presented at a medical meeting next year, Lilly said. Tirzepatide is commercialized for adults with obesity or with overweight who ...